Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBCs

Area of Science:

• Immunology
• Transfusion Medicine
• Biochemistry

Background:

• Red blood cells (RBCs) modified with methoxy-polyethylene glycol (PEG) using cyanuric chloride activation (CmPEG-RBCs) exhibit reduced immunogenicity compared to unmodified RBCs.
• This modification holds potential for mitigating alloimmunization in patients requiring chronic transfusions.

Purpose of the Study:

• To investigate the impact of CmPEG modification on the complement system, a key factor in transfusion rejection.
• To evaluate the efficacy of CmPEG-RBCs in preventing complement-mediated immune responses.

Main Methods:

• Incubation of CmPEG-RBCs with autologous and heterologous ABO-matched human serum.
• Assessment of complement activation pathways (classical and alternative), C3a generation, and C3b/C9 deposition.
• Evaluation of cell lysis using acidified serum and reactive lysis assays.
• Testing CmPEG-RBCs in ABO-mismatched serum to determine the role of ABO compatibility.

Main Results:

• CmPEG-RBCs did not activate the classical or alternative complement pathways, generate C3a, or undergo lysis in ABO-matched serum.
• Cell-bound complement regulation remained normal for CmPEG-RBCs.
• In ABO-mismatched serum, CmPEG modification failed to prevent lysis; in fact, lysis was enhanced at higher CmPEG concentrations (>1.0 mM).

Conclusions:

• Enhanced lysis in ABO-mismatched serum correlated with increased IgM binding, C3a generation, and C3b/C9 deposition.
• While PEGylation effectively masks non-ABO antigens, ABO blood group matching is still essential for preventing transfusion reactions.
• CmPEG-modified RBCs demonstrate significant potential for preventing alloimmunization once ABO compatibility is established.